Biotech | May 02, 2022
NORD announces over US $ 100,000 in grant funding available for rare disease research
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
Subscribe To Our Newsletter & Stay Updated
